NLS Agreement

Swedish pre-clinical biomarker assay company Offspring Biosciences and US spatial biology and biomarker analytics company Flagship Biosciences have announced a strategic partnership. The partnership aims to further advance precision drug development with a complete biomarker offering from discovery to companion diagnostics development, the companies state. “Together, Flagship Biosciences and Offspring Biosciences will provide a seamless […]

Norwegian biotech company Arxx Therapeutics will merge with Dutch pharma company Oxitope Pharma to create Calluna Pharma Inc. The merger followed a completed Series A round of EUR 75 million, led by the European investor Forbion, and included existing Arxx investors Sarsia, p53 and Investinor. The funding will last until late 2026, and will support […]

Qlucore has agreed a two-year license with Boehringer Ingelheim worth approximately SEK 1.67 million. The license enables global utilization of Qlucore Omics Explorer software, a software designed for research in pharmaceuticals and biotechnology, catering to both commercial and academic users. Through interactive visualization coupled with rapid calculations, users can identify crucial information within often vast […]

The Omega collaboration will leverage its platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. The Cellarity collaboration aims to unravel novel biological drivers of MASH and will leverage Cellarity’s platform to develop a small molecule therapy against this disease. […]

Orion Corporation and Glykos Finland have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs). Under the agreement, Orion gains access to Glykos’ ADC technologies, initiating an ADC program with the potential for expansion into two additional programs in the future. Orion will be responsible for the target selection, research, […]

AstraZeneca and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions. Preliminary results from the Phase I trial have shown a differentiating clinical profile for ECC5004, with good tolerability and encouraging glucose and body weight reduction across the […]